Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02000947 · ClinicalTrials.gov registry record · Phase 1
A Phase 1b Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Non-small Cell Lung Cancer
A Phase 1 study, sponsored by MedImmune.
- Completed
- Registry status
- Phase 1
- Development phase
- 459
- Enrollment target
NCT02000947: Completed Phase 1 study, sponsored by MedImmune.
NCT02000947 is a Phase 1 study that has completed, run by MedImmune. The registered enrollment target is 459 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (665% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02000947, a Phase 1 study, has completed, sponsored by MedImmune.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 459 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if MEDI4736 will be adequately tolerated in combination with tremelimumab in subjects with advanced non-small cell lung cancer (NSCLC).
Primary Outcome
The number of subjects reporting adverse events (AEs) and number (percentage) of subjects reporting serious adverse events (SAEs) as graded by CTCAE Version 4.03
Interventions
- DRUG Tremelimumab
- DRUG MEDI4736
- DRUG tremelimumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 459 participants |
| Start Date | 2013-10-25 |
| Est. Completion | 2019-09-17 |
| Phase | Phase 1 |
What the finished NCT02000947 record still lists
NCT02000947 is an interventional study that assigns participants to a tested intervention. The registered 459 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (665% higher).
The record links to 0 conditions, and to 3 interventions - of which Tremelimumab is the first listed.
NCT02000947 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02000947 about?
NCT02000947 is a clinical study titled "A Phase 1b Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Non-small Cell Lung Cancer". The purpose of this study is to determine if MEDI4736 will be adequately tolerated in combination with tremelimumab in subjects with advanced non-small cell lung cancer (NSCLC).
What is the current status of trial NCT02000947?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 459 participants. The study started on 2013-10-25. Estimated completion is 2019-09-17.
What interventions are being tested in trial NCT02000947?
The interventions under investigation include: Tremelimumab (DRUG), MEDI4736 (DRUG), tremelimumab (DRUG).
Who is sponsoring clinical trial NCT02000947?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02000947's enrollment target sits among peer trials
459 54th of 2000 higher than 1,947 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04452825 · 459 participants · NA
A New Psychotherapy Intervention for Older Cancer Patients
- NCT02977780 · 460 participants · Phase 2
INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)
- NCT03427736 · 460 participants
Anesthetics and Analgesics in Children
- NCT03819933 · 460 participants · NA
Optimizing Family Counseling for Anticipated Extremely Preterm Delivery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI